Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 15Terminated 6Recruiting 3Unknown 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 8Fallopian Tube Neoplasms 6Breast Neoplasms 5Sarcoma 3Ovarian Cancer Recurrent 3Carcinoma, Ovarian Epithelial 3Sarcoma, Ewing 2Neoplasm Metastasis 2Leiomyosarcoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Peritoneal Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Low Grade Serous Ovarian Cancer 1Liposarcoma 1Hodgkin Disease 1Histiocytoma, Malignant Fibrous 1HER2-negative Breast Cancer 1Gliosarcoma 1Glioblastoma 1Endometrial Neoplasms 1Dermatofibrosarcoma 1

Interventions

Paclitaxel 10Carboplatin 6Bevacizumab 5pembrolizumab 4Cyclophosphamide 4olaparib 3liposomal doxorubicin 3fludarabine 3ribociclib 2palbociclib 2mirvetuximab soravtansine 2Topotecan 2Nivolumab 2Letrozole 2Fulvestrant 2Blood Specimen Collection 2trastuzumab deruxtecan 1sacituzumab govitecan 1pegfilgrastim 1niraparib 1lenvatinib 1isoquercitrin 1fludarabine phosphate 1durvalumab 1cemiplimab 1abemaciclib 1Tinzaparin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1SLC25A33 protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Ovarian Epithelial × liposomal doxorubicin × Clear all
NCT06994195 2026-04-20

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Recruiting
384 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04516447 2026-04-07

MUIR

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

Phase 1 Recruiting
172 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07218809 2026-01-16

TREVI-OC-01

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡